经会阴磁共振融合靶向前列腺穿刺活检采用PrecisionPoint经会阴通路系统与网格模板的比较:结局评估
该研究比较PrecisionPoint与网格模板经会阴磁共振融合靶向前列腺穿刺活检对临床显著前列腺癌(csPCa)检出率和并发症的影响。纳入2020年8月1日至2024年9月1日间890例患者共1134个磁共振病灶,两组总体前列腺癌检出无差异,既往活检阴性患者中网格模板组csPCa检出率更高(P=.021),活检方式在患者水平(P=.797)和病灶水平(P=.473)均非csPCa的显著预测因子,并发症率低且两组相似。
要点
- 两组总体前列腺癌检出率无差异,前部磁共振病灶csPCa检出能力相似。
- 既往活检阴性患者中,网格模板组csPCa检出率高于PrecisionPoint组(P=.021)。
- 活检方式在患者水平(P=.797)和病灶水平(P=.473)均非csPCa显著预测因子。
核心结论
- 在该队列中,经会阴磁共振靶向前列腺穿刺活检采用PrecisionPoint与网格模板识别的前列腺癌率相似,包括前部磁共振病灶。
- 并发症率低,且不因技术不同而异。
研究设计与样本
- 查询前瞻性维护的前列腺活检数据库,纳入2020年8月1日至2024年9月1日间接受经会阴磁共振融合靶向前列腺穿刺活检(包括同期系统活检)的18-89岁男性。
- 共分析890例患者的1134个磁共振病灶(PrecisionPoint组:542例患者/714个病灶;网格模板组:348例患者/420个病灶)。
- 主要结局为磁共振感兴趣区内csPCa检出;在患者水平检查30天并发症和总体csPCa率;亚组结局包括前部磁共振病灶的癌症检出和按既往活检状态分层;采用逻辑回归分析。
主要发现
- 两组总体前列腺癌检出无差异。
- 既往活检阴性的患者中,网格模板方法检出的csPCa率更高(P=.021)。
- 逻辑回归显示,活检方式在患者水平(P=.797)或病灶水平(P=.473)均非csPCa的显著预测因子。
- 两种方法并发症率和前部病灶csPCa检出能力相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare PrecisionPoint and grid-based biopsies on rates of clinically significant prostate cancer (csPCa) detection and complications when transperineal MRI-fusion targeted biopsy is performed. MATERIALS AND METHODS: We queried a prospectively maintained prostate biopsy database to identify men ages 18-89 who underwent transperineal MRI-fusion targeted prostate biopsies (including concurrent systematic biopsies) between August 1, 2020 and September 1, 2024. The primary outcome was detection of csPCa in the MRI region of interest. 30-day complications and overall rates of csPCa were examined at the patient level. Subgroup outcomes included cancer detection in anterior MRI lesions and stratification by prior biopsy status. Logistic regression was performed. RESULTS: 1134 MRI lesions in 890 patients were included in the analysis (PrecisionPoint: 542 patients/714 lesions; grid-based biopsy: 348 patients/420 lesions). There were no differences in prostate cancer detection between the two groups overall. For patients with a prior negative biopsy, a grid-based approach detected a higher rate of csPCa (P=.021). On logistic regression, biopsy approach was not a significant predictor of csPCa at either the patient (P=.797) or lesion (P=.473) levels. Complication rates and the ability to detect csPCa in anterior lesions were similar between approaches. CONCLUSION: PrecisionPoint and grid-based biopsies identified similar rates of prostate cancer, including in anterior MRI lesions, when transperineal MRI-targeted prostate biopsy was performed in this cohort. Complication rates were low and did not differ based on technique.
引用
- Buller D, Lin F, Wagner J, et al. Transperineal Magnetic Resonance Imaging-Fusion Targeted Prostate Biopsy Utilizing the PrecisionPoint Transperineal Access System vs a Grid Template: An Assessment of Outcomes. Urology. 2025. PMID: 39892576. doi:10.1016/j.urology.2025.01.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。